HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
In This Section
Allison Barz Leahy, MD, MSCE
Attending Physician
Dr. Leahy studies the use of patient-reported outcomes (PROs) for symptom monitoring in pediatric oncology and how they can improve clinical outcomes. She is also interested in how PROs can be leveraged to inform predictive models for novel therapeutics, such as CAR T-cell therapy.
Education and Training
MA, Hunter College of the City of New York (Biological Sciences)
MD, SUNY Upstate Medical University, Syracuse
Internship, Children’s Hospital of Philadelphia (Pediatrics)
Residency, Children’s Hospital of Philadelphia (Pediatrics)
Fellowship, Children’s Hospital of Philadelphia (Pediatric Hematology/Oncology)
Fellowship, Children’s Hospital of Philadelphia (Pediatric Bone Marrow Transplant and Immunotherapy)
Research Training Program, Children’s Hospital of Philadelphia (Pediatric Hospital Epidemiology and Outcomes)
MSCE, University of Pennsylvania
Titles and Academic Titles
Attending Physician
Assistant Professor of Pediatrics
Professional Memberships
American Society of Clinical Oncology, 2014-
Children’s Oncology Group, 2015-
American Society of Pediatric Hematology and Oncology, 2016- American Society of Hematology, 2017-
American College of Epidemiology, 2017-
International Society for Quality of Life Research, 2017-
Professional Awards
American Society of Hematology Clinical Research Training Program Fellow, 2017-2018
Recipient of NIH Loan Repayment Program in Pediatric Research, 2017-
American Society of Hematology Clinical Research Training Program Fellow, 2017-2018
Dracker Family Scholarship, 2011
Jack J. Schneider Scholarship, 2011
Commendation, Outstanding Performance in Clinical Years, SUNY Upstate College of Medicine, 2011
Gold Humanism Honor Society, 2011
Alpha Omega Alpha, 2011
Publication Highlights
Pubmed:
Leahy AB, Devine KJ, Li Y, Liu H, Myers R, DiNofia A, Wray L, Rheingold SR, Callahan C, Baniewicz D, Patino M, Newman H, Hunger SP, Grupp SA, Barrett DM, Maude SL. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood. 2022 Apr; 139(14): 2173-2185. PMID: 34781373
Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, Dolan JG, Callahan C, Baniewicz D, Devine K, Wray L, Aplenc R, June CH, Grupp SA, Rheingold SR, Maude SL. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021 Oct; 8(10): e711-e722. PMID: 34560014
Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2021 Sep; 39(27): 3044-3055. PMID: 34156874
Leahy AB, Schwartz LA, Li Y, Reeve BB, Bekelman JE, Aplenc R, Basch EM. Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy. Cancer. 2021 Aug; 127(16): 2980-2989. PMID: 33945640
Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, Gladney WL, Lacey SF, Liu H, Maude SL, McGuire R, Motley LS, Teachey DT, Wertheim GB, Wray L, DiNofia AM, Grupp SA. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: A prospective clinical trial. J Clin Oncol. 2021 Jan; (online ahead of print). PMID: 33417474